Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sales of Class 1 OTC Drugs Down Following Full Implementation of Amended PAL: JACDS
June 29, 2009
- REGULATORY NEWS IN BRIEF
June 29, 2009
- JACDS Approves Tadayuki Teranishi as New President
June 29, 2009
- DSUR (E2F) Fails to Reach Step 4 in Yokohama: ICH
June 29, 2009
- SELF-MEDICATION NEWS IN BRIEF
June 29, 2009
- Various Intellectual Properties Should Be Used for Lifecycle Management: Prof. Yamana
June 29, 2009
- OPINION／High Price for Executive Search in Japan
June 29, 2009
- Patents on New DDS Formulations with Known API, Indications May Become Eligible for Patent Period Restoration
June 29, 2009
- 45 Univ. Hospitals to Consider Joint Purchases
June 29, 2009
- New Dosage, Treatment Regimens Expected to Become Patentable
June 29, 2009
- GENERICS NEWS IN BRIEF
June 29, 2009
- Revised Pricing Rule Had Little Effect on Pricing of New Drugs in FY2008: FPMAJ
June 29, 2009
- Prof. Kudo Calls For Proper Use of Nexavar for HCC
June 29, 2009
- Range of Drugs Eligible for Price Protection Proposed by FPMAJ Is Reasonable: Report
June 29, 2009
- Sorafenib May Be Used in Wide Range of Patients
June 29, 2009
- Sales of Ethical Drugs Up 0.2% in April
June 29, 2009
- Taiyo Aims at Sales of Over ¥50 Bil. with 227 MRs in FY2009
June 22, 2009
- R&D NEWS IN BRIEF
June 22, 2009
- Top-Four Generic Firms' Business Grows by Leaps and Bounds
June 22, 2009
- Gov't to Consider Patent Rights on Treatment Regimens
June 22, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…